Payers see price leverage with entry of Merck hepatitis C drug
January 29, 2016 at 13:40 PM EST
Jan 29 (Reuters) - U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.
